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Abstract
PURPOSE—Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to 
anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple 
negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in 
TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC.
PATIENTS AND METHODS—The study population includes 190 patients with stage I-III 
TNBC treated uniformly on two independent prospective cohorts. All patients were prescribed NA 
chemotherapy regimen of Cb (AUC 6) + D (75mg/m2) given every 21 days × 6 cycles. 
Pathological complete response (pCR: no evidence of invasive tumor in the breast and axilla) and 
Residual Cancer Burden (RCB) were evaluated.
RESULTS—Among 190 patients, median tumor size was 35mm, 52% Lymph Node positive and 
16% had germline BRCA1/2 mutation. The overall pCR and RCB 0+1 rates were 55% and 68%, 
respectively. pCR in patients with BRCA associated and wild-type TNBC were 59% and 56%, 
respectively (p=0.83). On multivariable analysis stage III disease was the only factor associated 
with a lower likelihood of achieving a pCR. 21% and 7% of patients, respectively, experienced at 
least one grade 3 or 4 adverse event.
CONCLUSION—The CbD regimen was well tolerated and yielded high pCR rates in both 
BRCA associated and wildtype TNBC. These results are comparable to pCR achieved with 
addition of Cb to anthracycline-taxane chemotherapy. Our study adds to the existing data on the 
efficacy of platinum agents in TNBC and supports further exploration of the CbD regimen in 
randomized studies.
Introduction
Triple negative breast cancer (TNBC) accounts for 15% of all breast cancers, and is 
associated with poor long-term outcomes compared to other breast cancer subtypes(1–5). 
TNBC is a chemosensitive disease and therefore adjuvant chemotherapy is generally 
recommended for TNBC patients with stage I (T>1cm)-III disease(6, 7). However, despite 
receiving standard anthracycline-taxane based chemotherapy, a significant proportion (30–
40%) of patients with early stage TNBC develop metastatic disease and succumb to the 
cancer(4, 5, 8). Thus, improved therapeutic approaches are desired for TNBC. Since no 
molecular actionable targets have been identified in TNBC so far, modifications of the 
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traditional breast cancer chemotherapy regimens (i.e., the addition of carboplatin) are a 
potential way of improving patient outcomes.
Sporadic and germline BRCA mutation associated TNBC share several pathological and 
molecular similarities(9–13). These similarities have led to the exploration of DNA 
damaging agents like platinum compounds in the general population of patients with 
TNBC(14–17). While only 15–20% of TNBC patients harbor germline BRCA mutations, 
homologous recombination DNA repair deficiency is likely present in a much larger fraction 
of TNBC patients(15, 17–21). Currently it is not very clear if the efficacy of platinum salts 
will predominantly be restricted to BRCA mutation-associated TNBC or will these agents 
provide meaningful benefit in a larger fraction of sporadic TNBC(15, 22–24). Recent studies 
demonstrate that addition of carboplatin to anthracycline and taxane based neoadjuvant 
chemotherapy (NAC) improves pathological complete response (pCR) in unselected TNBC 
patients (14, 16, 25, 26). However, this improvement in pCR rate comes at the cost of a 
significant increase in toxicity (14, 16). Furthermore, anthracyclines and cyclophosphamide 
although very active for treatment of breast cancer, have established small but serious long 
term risks (secondary leukemia/myelodysplastic syndrome, cardiomyopathy)(27–29).
Therefore, the exploration of the activity of anthracycline-free chemotherapy regimens in 
TNBC is desired. Taxanes exhibit significant activity in TNBC and also demonstrate 
preclinical synergy with platinum agents thus, providing a rationale for evaluation of 
platinum-taxane combination in TNBC (30–33). Here-in we report a combined analysis of 
two separate TNBC cohorts (University of Kansas and Spanish MMJ-CAR-2014-01) treated 
with a uniform NAC regimen of carboplatin and docetaxel.
Patients and Methods
Patient Population
University of Kansas (KU) cohort—Patients with Stage I (T≥1 cm), II and III TNBC 
presenting at an academic center and five community practices within the Kansas City 
metropolitan area were approached for participation in an IRB approved prospective registry 
protocol (P.R.O.G.E.C.T. NCT02302742). Eligible female patients had biopsy proven 
invasive breast cancer not previously treated with taxanes, anthracyclines or carboplatin for 
any malignancy. Triple negativity was defined as estrogen receptor (ER) and progesterone 
receptor (PgR) immunohistochemical (IHC) nuclear staining of less than 10% and HER2 
IHC staining 0 to 1+ or fluorescence in situ hybridization (FISH) ratio<2.0 if IHC 2+ or IHC 
not performed (ASCO/CAP Guideline recommendations for HER2 Testing in breast cancer) 
(34). From 2011 to 2015, 69 enrolled patients with stage I (T>1cm) II and III TNBC were 
treated with NAC regimen of carboplatin + docetaxel.
MMJ-CAR-2014-01cohort—GOMHGUGM022011 is a prospective, multicenter, non-
randomized trial exploring the anti-tumor activity of neoadjuvant CbD (AEMPS code MMJ-
CAR-2014-01, NCT01560663). Eligible patients included females with pathologically 
confirmed diagnosis of primary invasive breast cancer, stage II-III (T≥ 2cm) aged >18 years, 
and not previously treated with taxanes, anthracyclines or carboplatin for any malignancy. 
The patients were diagnosed at any of the participant academic institutions (see 
Sharma et al. Page 3
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
supplemental material for list of participating institutions) and were able to sign the IRB 
approved informed consent at each of the centers. Triple negativity was defined as ER and 
PgR nuclear staining of less than 1% by IHC, and HER2 IHC staining 0 to 1+ or FISH ratio 
< 2.0 if IHC 2+ or IHC not performed (ASCO/CAP Guideline recommendations for HER2 
Testing in breast cancer (34). Between 2010 and 2015, 123 patients with stage II and III 
TNBC were enrolled, and treated with NAC regimen of carboplatin + docetaxel.
Study Procedures
Patients in both cohorts were prescribed NAC regimen of carboplatin (AUC 6) + docetaxel 
(75mg/m2) given every 21 days for 6 cycles. All patients received myeloid growth factor 
support (KU cohort: 6 mg peg-filgrastim on D2, Spanish cohort: filgastrim 300 
micrgram/day × 5–7 days after chemotherapy according to the guidelines of each 
institution). In patients with clinically suspicious axillary lymph node/s, histological 
confirmation by biopsy or fine-needle aspiration was encouraged. Patients with clinically 
negative axillary lymph nodes could undergo pretreatment sentinel lymph node (SLN) 
sampling. Following NAC, all patients underwent breast surgery. Axillary sampling was 
required except in patients with pretreatment negative SLNs, but the extent of axillary 
surgery and subsequent irradiation were determined by the treating physician as was 
postoperative adjuvant therapy.
Pathologic Evaluation
Pathologic response was determined locally, without central pathologic review. All surgical 
pathology reports were centrally reviewed by the PIs of the respective cohorts. pCR was 
defined as the absence of residual invasive disease with or without ductal carcinoma in situ 
in the breast and axilla (ypT0/isN0). Patients with pCR in the breast and negative 
pretreatment SLNs were considered to have achieved pCR. Residual cancer burden (RCB) 
was recorded by local pathologists for all patients using the classification by Symmans et al. 
(35). Patients achieving pCR (RCB 0) or near pCR (RCB 1) are assessed within the group 
RCB 0+1.
Germline BRCA1/2 Testing
KU cohort—Germline testing for BRCA1/2 was done utilizing commercially available 
tests and laboratories. The majority of the patients (97%) had testing through Myriad 
Genetic Laboratories (comprehensive BRACAnalysis™ or myRisk™ Hereditary Cancer 
test), 3% had testing through other laboratories (BreastNext™, Ambry genetics), 
(OncoGeneDx™, GeneDx).
Spanish cohort—Germline testing for BRCA1/2 was done at Sistemas Genómicos 
facilities using Targeted Next Generation by sequencing of 7 genes (BRCA1, BRCA2, 
PALB2, BARD1, RAD50, RAD51C, RAD51D) and MLPA by quantification of probes 
corresponding to BRCA1, BRCA2 genes using the MLPA kit according to the 
manufacturer’s recommendations (MRC-Holland), fragment analysis by ABI 3730xl genetic 
analyzer and data normalization and interpretation of results using Coffalyser.net software as 
recommended by MRC-Holland. Only BRCA1 and BRCA2 testing are available and 
reported for this analysis.
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According to BRCA1 and 2 results, patients were counseled in both cohorts as per 
institutional guidelines.
Data Collection and Statistical Methods
Relevant demographic, treatment and outcome variables of the Spanish and KU cohorts 
were combined for analysis. An independent statistical analysis of the combined data set 
was performed by both groups and any discrepancies between the two independent analyses 
were resolved by review of source documents.
Statistical section—Primary objective was to determine the rate of pathological complete 
response (pCR) and near pCR as defined above. All analyses were conducted using SPSS 
statistics version 22 (IBM corporation). All reported p values were two-sided without 
corrections for multiple comparisons. p values less than 0.05 were considered to indicate 
statistically significant results. Overall frequencies and percentages were summarized for 
race, ethnicity, menopausal status, T-stage, lymph node status, TNM stage, hormone receptor 
status, germline BRCA mutation status, surgery type, and family history of breast/ovarian 
cancer (36). Patient outcomes were summarized in terms of pCR, and RCB. Confidence 
intervals for the proportion of patients, who achieved pCR, and RCB 0+1, were calculated 
according to the exact two-sided binomial test. Categorical variables were compared 
between the two cohorts by Fisher’s exact test. Continuous variables were compared by non-
parametric Mann-Whitney test. Logistic regression analysis was used to examine the effect 
of multiple variables on attainment of pathological response (pCR; RCB 0 + 1).
Results
Study Cohort
Consort diagram depicting cohort identification has been provided (figure 1). Two patients 
in the Spanish cohort were found to have metastatic disease after enrollment and were 
excluded from intention to treat (ITT) population. Seven patients in the ITT population were 
not included in the per protocol analysis (received less than four cycles of NAC without 
progression=5, lost to follow up =2). Eight patients switched to a different chemotherapy 
regimen due to clinically progressive disease and are designated as “no pCR” in per protocol 
analysis. In addition one subject died due to disease progression during NAC chemotherapy 
and is also included in per protocol analysis (designated as “no pCR”).
Patient Characteristics
The study population included 190 subjects treated in KU and Spanish cohorts between 
2010 and 2015. Table 1 describes the demographic and baseline clinical characteristics of 
the study population. For the overall study population median age was 51 years (range 29–
81 years), 14% Hispanic, and 7% were black. Fifty-six percent had clinical stage II disease, 
and 52% were clinically node positive. Germline BRCA testing results were available for 
87% of the study population and 16% of the study population carried a deleterious 
BRCA1/2 mutation. A small percentage (5%, all from KU cohort) of patients had ER/PgR 
expression between 1–10%. Compared to the KU cohort, patients in the Spanish cohort had 
larger tumors, and higher percentage of node positive and stage III disease. Family history 
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was assessed in the two cohorts based on the local guidelines (specific guidelines are 
provided in supplement section). Twenty-eight percent of patients reported a positive family 
history of breast or epithelial ovarian cancer (KU: 39%, Spanish cohort: 21%). To provide 
consistent evaluation of family history, when the Spanish family history criteria was applied 
to the entire study population 24% (45/190) of patients demonstrated positive family history.
Treatment Response
Pathological complete response and RCB 0+1 for the per protocol study population was 
55% (95% CI: 48–62%) and 68% (95% CI: 61%, 75%), respectively. Both pCR and RCB 
0+1 rates were higher in the KU cohort compared to the Spanish trial (Table 2). pCR and 
RCB 0+1 rates were lower in stage III disease compared to stage I-II disease (pCR: 37% vs. 
63% p=.002; RCB 0+1: 49% vs. 77%, p=<.001). When assessed by individual TNM stage, 
the pCR rates were similar in the KU and Spanish cohorts (Table 2). When assessed by 
germline BRCA status, pCR rate was 56% in BRCA wild type and 59% in BRCA mutation-
associated TNBC (p=0.83) (Figure 2). Family history of breast and ovarian cancer did not 
impact pCR or RCB 0+1 rates using individual cohort positive family history criteria 
(Supplemental Table 1) or using Spanish trial positive family history criteria (data not 
shown).
Due to the inclusion of a small number of patients with 1–10% ER/PgR expression (KU 
cohort), pCR analysis was also performed according to ER/PgR expression status. Fifty and 
55% percent of patients with ER/PgR1–10% (n=6) and ER/PgR <1% (n=177) achieved 
pCR, respectively (Supplemental Table 2, p=1.0).
On univariate analysis presence of lower T stage (T1/2 vs. T3/4), lower TNM stage (I/II vs. 
III) and being treated in the KU cohort were associated with higher likelihood of achieving a 
pCR (Table 3). For RCB 0+1 presence of lower T stage (T1/2 vs. T3/4), lower TNM stage 
(I/II vs. III), lymph node negative status and being treated in the KU cohort were associated 
with higher likelihood of achieving a RCB 0+1 (Supplemental Table 3). Age, germline 
BRCA mutation and family history of breast/ovarian cancer did not influence the likelihood 
of achieving pCR or RCB 0+1. Compared to the KU cohort the Spanish cohort had a higher 
proportion of patients with stage III disease and on multivariable logistic regression analysis 
the presence of TNM stage III disease was the only factor associated with a lower likelihood 
of achieving a pCR (HR 0.35, 95% CI: 0.19, 0.67) (factors included in multivariable 
analysis: age, lymph node status, T stage, TNM stage, germline BRCA mutation status, 
family history and cohort type).
Adverse Events
Twenty-eight percent (54/190) of patients experienced one or more grade 3/4 adverse events 
(Grade 3=21%, Grade 4=7%) (Table 4). Eighty-three percent of patients completed all 6 
cycles of treatment. Twelve percent (22/183) of patients discontinued treatment prematurely: 
4.4% (8/183) because of progressive disease, 6.0% (11/183) because of toxicity, 1.6% 
(3/183) because of other reasons. No treatment related deaths were reported.
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Discussion
Triple negative breast cancer, which is defined by the lack of ER and PgR expression and 
absence of HER2 over expression and/or gene amplification, is currently the most lethal 
subtype of breast cancer. Due to the lack of molecular targets, chemotherapy is the only 
available treatment for TNBC. Despite achieving higher rates of pCR with conventional 
neoadjuvant chemotherapy, TNBC phenotype is associated with higher relapse rates than 
luminal tumors among patients with residual disease (1, 4, 5, 37). Although current 
guidelines recommend anthracycline and taxane-based chemotherapy for (neo)adjuvant 
treatment of TNBC, these schedules have limitations (6, 7). First of all, the studies that 
support this recommendation included patients irrespective of HER 2 and/or ER status. 
Second, anthracyclines are associated with established irreversible and long-term adverse 
events and finally 30–40% of patients with early TNBC experience relapse despite receiving 
anthracycline-taxane based (neo)adjuvant treatment (8, 27–29, 38, 39).Thus, there is a need 
to design clinical trials in this population of patients incorporating new drugs and/or 
optimizing the administration of standard chemotherapy to improve the efficacy and reduce 
the toxicity.
Recent studies demonstrate that addition of platinum salts, namely carboplatin, to 
anthracycline and taxane based neoadjuvant chemotherapy improves pathological complete 
response in TNBC(14, 16, 25, 26). However, this improvement in pCR rate comes at the cost 
of an increase in toxicity and decrease in tolerability of chemotherapy (14, 16). The efficacy 
of anthracycline-devoid neoadjuvant combinations in sporadic and BRCA associated TNBC 
has not been properly explored so far. Over a decade ago a few neoadjuvant studies 
evaluated platinum-taxane combination chemotherapy in unselected locally advanced breast 
cancer patients. These studies demonstrated overall modest pCR rates of 14–22% with 
higher pCR rates noted in the ER negative subgroup (40, 41). Over the last few years 
improved understanding of biology of breast cancer subtypes coupled with the preclinical 
data supporting activity of platinum agents in TNBC has led to re-emergence of interest in 
exploration of platinum agents for treatment of TNBC (14, 16, 25, 26).Taxanes are an 
integral part of adjuvant/neoadjuvant chemotherapy regimens for breast cancer treatment and 
appear to contribute particularly among patients with TNBC(30). On the other hand, there is 
abundant preclinical and clinical data demonstrating synergy between platinum compounds 
and taxanes in several solid tumor types (31–33) . An interesting study, the randomized TNT 
trial, compared single agent carboplatin to single agent docetaxel in metastatic TNBC 
patients. The trial showed both significant single agent activity of docetaxel and carboplatin 
in unselected TNBC and non-cross resistance between these agents (22). Furthermore, in a 
randomized neoadjuvant study comparing single agent docetaxel versus single agent 
doxorubicin, the taxane demonstrated a significant superior activity with respect to single 
agent doxorubicin in cDNA microarray-defined basal-like TNBC, but not in the remaining 
subtypes (42). The above clinical and preclinical data provided the rationale for the two 
different studies (the KU and the Spanish trials) that were conducted in parallel and whose 
merged results are presented in this article. Both evaluated the antitumor activity of an 
identical neoadjuvant combination chemotherapy regimen of carboplatin plus docetaxel in 
TNBC.
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The merged results presented here show that the pCR rates achieved with this CbD 
chemotherapy regimen in TNBC seem to be numerically higher than as those reported in 
several trials using classical neoadjuvant anthracycline-taxane combinations, in which 28–
39% of TNBC patients achieved a pCR (14, 43, 44). This pCR rate of 55% was achieved 
even though more than half of the patients had node positive disease and a third had stage III 
disease. Previous studies have demonstrated that pathological complete response is a very 
robust surrogate for improved long term outcomes, specifically for aggressive tumor 
subtypes like TNBC (1, 45). Thus, pCR is considered as a good end point for early 
evaluation of new treatment approaches for TNBC.
Addition of carboplatin to anthracycline/taxane based chemotherapy in TNBC increases 
pathological complete responses from around 40% to 50–54% (14, 16, 25),. However, the 
impact of this approach on long term outcomes is not yet clear. In GeparSixto a 44% 
improvement in 3-year Event free survival (EFS) was noted with the addition of concurrent 
carboplatin to anthracycline plus taxane plus bevacizumab chemotherapy backbone. On the 
other hand, in CALGB 40603 addition of carboplatin to taxane followed by sequential 
doxorubicin/cyclophosphamide did improve pCR rate but, improvement in 3 year EFS or 
overall survival (OS) was not noted (46, 47). It is important to point out that, neither of these 
two trials were powered sufficiently for EFS and OS end points and thus cannot be 
considered definitive studies to answer the question of clinical utility of platinum agents for 
early stage TNBC. The optimal dose, sequence and chemotherapy backbone for efficacious 
incorporation of platinum in treatment of early stage TNBC are also not yet known. Several 
ongoing randomized phase III trials are evaluating various schedules and combinations of 
platinum salts in early stage TNBC (NCT02488967, NCT02455141, NCT02441933, 
NCT02445391, NCT02125344, NCT02032277).
Pathological complete response in our study with the CbD regimen was 55% which is 
similar to pCR attained with addition of carboplatin to anthracycline/taxane chemotherapy. 
However, the addition of carboplatin to anthracycline-taxane regimens is associated with a 
significant increase in acute toxicity with only 50–76% of patients completing all study 
treatment (14, 16, 25). In contrast, chemotherapy regimen of CbD has a much favorable 
toxicity profile with 83% of patients completing all 6 cycles of therapy.
There were some differences between the KU and Spanish cohorts. Compared to the KU 
cohort, patients in the Spanish cohort had higher disease burden (larger tumors, more node 
positive and stage III disease). Patients in the Spanish cohort were also more likely to 
undergo sentinel lymph node biopsy (SLNB) prior to NAC (35% vs 0% p<0.0001) and to 
undergo breast conservation surgery (vs. mastectomy). These surgical differences are a 
reflection the local surgical practice patterns and patient preference regarding breast 
conservation in the respective countries. The percentage of patients with deleterious BRCA 
mutation in the KU series is consistent with other reported studies from the United States 
(15, 19). The Spanish series reported a slightly lower percent of patients with deleterious 
BRCA mutations, but this prevalence rate is also consistent with the reported rates in 
Spanish women with TNBC non-selected for family history(48, 49). We noted a pCR rate of 
59% in BRCA mutation carriers, which is consistent with previously reported pCR rates 
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with single agent platinum and platinum-anthracyline-taxane combination chemotherapy in 
BRCA mutation carriers(24, 50).
In our study, deleterious BRCA mutation and family history were not associated with pCR 
and RCB 0+1 with equally good pathological response rates noted in BRCA wild type and 
mutant patients. This might be explained by the idea that docetaxel and carboplatin 
combination offers antitumor coverage for both sporadic and BRCA-associated TNBC. 
Docetaxel seems to be better in the first group, while carboplatin is more active in BRCA-
mutated patients. Furthermore, it is now becoming increasingly evident that 40–50% of 
BRCA wild type TNBC harbor homologous recombination deficiency and benefit of 
platinum agents may very well extend much beyond BRCA mutation associated breast 
cancers (15, 17, 21). The tolerance to CbD was good. Only 6% of patients discontinued 
therapy because of toxicity. A similar chemotherapy regimen, the TCH regimen (that 
combines carboplatin and docetaxel with trastuzumab), is widely used for the neo/adjuvant 
treatment of HER-2 positive breast cancer.
Although presenting very robust pathological response data our study does have several 
limitations. The decision to combine the two series with the purpose of reporting 
pathological response was made post hoc and was not preplanned. However, this report 
includes almost 200 TNBC patients treated with the same regimen in three different 
continents. In this combined analysis more than half of the patients had node positive 
disease, a third had stage III disease and 16% harbored deleterious BRCA mutation. These 
patient characteristics are very similar to contemporary randomized neoadjuvant clinical 
trials in TNBC. We also acknowledge the lack of a control arm in both series; a deficit 
which can only be addressed in setting of a randomized trial. In fact, an ongoing randomized 
phase II study is currently comparing neoadjuvant CbD regimen to the anthracycline-taxane-
carboplatin regimen used in CALGB 40603 (NCT02413320).
In conclusion, the combination of carboplatin plus docetaxel with G-CSF support yielded a 
significant antitumor activity in stage I-III TNBC with manageable toxicity. This 
anthracycline-free regimen should be compared to standard taxane-anthracycline 
chemotherapy as neoadjuvant therapy of TNBC in a prospective randomized trial.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Acknowledgement of research support: The KU PROGECT Registry was supported by the University of Kansas 
Research Career Award and the University of Kansas Cancer Center’s CCSG (P30 CA168524) Biospecimen 
Repository Core Facility.
Funding for M Martin was supported by research grant from Instituto de Salud Carlos III (ISCIII, PI 12/02684) and 
FEDER (RETICC-RD12/0036/0076). “Ayuda cofinanciada por el Fondo Europeo de Desarrollo Regional 
(FEDER). Una manera de hacer Europa”). CM Perou was supported by funds from the NCI Breast SPORE 
program P50-CA58223.
Sharma et al. Page 9
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
REFERENCES
1. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant 
therapy and long-term survival in patients with triple-negative breast cancer. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2008; 26:1275–1281. 
[PubMed: 18250347] 
2. Osborne CR, Kannan L, Xie XJ, Ashfaq R, Bian A, Baylor TD. Neoadjuvant chemotherapy for 
basal-like breast cancer cohort: clinical and pathological outcomes. Breast Cancer Research and 
Treatment. 2006; 100:S53.
3. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual Report to 
the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by 
Race/Ethnicity, Poverty, and State. Journal of the National Cancer Institute. 2015; 107:djv048. 
[PubMed: 25825511] 
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast 
cancer: clinical features and patterns of recurrence. Clinical cancer research : an official journal of 
the American Association for Cancer Research. 2007; 13:4429–4434. [PubMed: 17671126] 
5. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: 
primary tumor chemosensitivity of breast cancer subtypes. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2007; 13:2329–2334. [PubMed: 
17438091] 
6. NCCN. [cited 2013; 3.2014] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) 
Breast Cancer. 2014. [Available from: http://www.nccn.org/professionals/physician_gls/pdf/
genetics_screening.pdf
7. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring 
therapies-improving the management of early breast cancer: St Gallen International Expert 
Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology : official 
journal of the European Society for Medical Oncology / ESMO. 2015; 26:1533–1546.
8. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and 
distant metastasis in conservatively managed triple negative early-stage breast cancer. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24:5652–
5657. [PubMed: 17116942] 
9. Prat A, Cruz C, Hoadley KA, Diez O, Perou CM, Balmana J. Molecular features of the basal-like 
breast cancer subtype based on BRCA1 mutation status. Breast cancer research and treatment. 2014; 
147:185–191. [PubMed: 25048467] 
10. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 
mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer 
Institute. 2003; 95:1482–1485. [PubMed: 14519755] 
11. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction 
in sporadic basal-like breast cancer. Oncogene. 2007; 26:2126–2132. [PubMed: 17016441] 
12. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal 
abnormalities in basal-like human breast cancer. Cancer cell. 2006; 9:121–132. [PubMed: 
16473279] 
13. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, et al. High 
frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 
luminal breast tumors. Cancer Res. 2009; 69:663–671. [PubMed: 19147582] 
14. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the 
Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed 
by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in 
Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol. 2014
15. Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, et al. Phase II Study of 
Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and 
BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of 
Genomic Instability: PrECOG 0105. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2015; 33:1895–1901. [PubMed: 25847929] 
Sharma et al. Page 10
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant 
carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; 
GBG 66): a randomised phase 2 trial. The Lancet Oncology. 2014; 15:747–756. [PubMed: 
24794243] 
17. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: A Multicenter 
Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-
Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2015; 33:1902–1909. [PubMed: 25847936] 
18. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and 
outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. 
Clinical cancer research : an official journal of the American Association for Cancer Research. 
2011; 17:1082–1089. [PubMed: 21233401] 
19. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA 
mutation evaluation in a prospective triple-negative breast cancer registry: implications for 
hereditary breast and/or ovarian cancer syndrome testing. Breast cancer research and treatment. 
2014; 145:707–714. [PubMed: 24807107] 
20. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast 
cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for 
family history of breast cancer. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2015; 33:304–311. [PubMed: 25452441] 
21. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, et al. Genomic 
patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified 
carboplatin-based chemotherapy. Breast cancer research : BCR. 2014; 16:R47. [PubMed: 
24887359] 
22. Tutt AEPKL, Gilett C, Pinder S, Abraham J, Barrett S, Barrett-Lee P, Chan S, Cheang M, Fox L, 
Grigoriadis A, Harper-Wynne C, Hatton M, Kernaghan S, Owen J, Parker P, Rahman N, Roylance 
R, Smith I, Thompson R, Tovey H, Wardley A, Wilson G, Harries M, Bliss J. The TNT trial: A 
randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with 
metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/
07/012). 2014 Abstract S3-01, 2014. 
23. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant 
Cisplatin in triple-negative breast cancer. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2010; 28:1145–1153. [PubMed: 20100965] 
24. Von Minckwitz GHE, Fasching PA, Hauke J, Schneeweiss A, Salat C, Rezai M, Blohmer JU, 
Zahm DM, Jackisch C, Gerber B, Klare P, Kummel S, Eidtmann H, Paepke S, Nekljudova V, Loibl 
S, Untch M, Schmultzler RK. Pathological complete response (pCR) rates after carboplatin-
containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and 
triple-negative breast cancer (TNBC): Results from GeparSixto. Journal of Clinical Oncology. 
2014; 32
25. Rugo, HSOO., DeMichele, A., et al. Veliparib/carboplatin plus standard neoadjuvant therapy for 
high-risk breast cancer: First efficacy results from the I-SPY2 trial. San Antonio Breast Cancer 
Symposium; 2013. 
26. Tamura KHJ, Tsuda H, Yoshida M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, 
Yamamoto N, Inoue K, Ohno S, Kuroi K, Sukigara T, Fujiwara Y, Andoh M. Randomized phase II 
study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/
epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast 
cancer. Journal of Clinical Oncology. 2014; 32
27. Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M. Anthracycline-Induced 
Cardiomyopathy in Adults. Comprehensive Physiology. 2015; 5:1517–1540. [PubMed: 26140726] 
28. Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, et al. Risk of marrow 
neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network 
experience. J Clin Oncol. 2015; 33:340–348. [PubMed: 25534386] 
29. Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, et al. Cancer 
Therapy-Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues. 
Circulation. 2012; 126:2749–2763. [PubMed: 23212997] 
Sharma et al. Page 11
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
30. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. HER2 and Response to 
Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine. 2007; 357:1496–
1506. [PubMed: 17928597] 
31. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. 
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III 
and stage IV ovarian cancer. The New England journal of medicine. 1996; 334:1–6. [PubMed: 
7494563] 
32. Engblom P, Rantanen V, Kulmala J, Helenius H, Grenman S. Additive and supra-additive 
cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. British journal of 
cancer. 1999; 79:286–292. [PubMed: 9888470] 
33. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a 
single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-
analysis. Jama. 2004; 292:470–484. [PubMed: 15280345] 
34. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. 
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: 
American Society of Clinical Oncology/College of American Pathologists Clinical Practice 
Guideline Update. Journal of Clinical Oncology. 2013
35. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual 
breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 
25:4414–4422. [PubMed: 17785706] 
36. Sobin LH, Fleming ID. TNM classification of malignant tumors. cancer (fifth). 1997; 80:1803–
1804. [PubMed: 9351551] 
37. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer 
molecular subtypes respond differently to preoperative chemotherapy. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 2005; 11:5678–5685. [PubMed: 
16115903] 
38. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and 
Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clinical Cancer 
Research. 2004; 10:5367–5374. [PubMed: 15328174] 
39. Tan D, Marchió C, Jones R, Savage K, Smith I, Dowsett M, et al. Triple negative breast cancer: 
molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast 
Cancer Research and Treatment. 2008; 111:27–44. [PubMed: 17922188] 
40. Lee YJ, Doliny P, Gomez-Fernandez C, Powell J, Reis I, Hurley J. Docetaxel and cisplatin as 
primary chemotherapy for treatment of locally advanced breast cancers. Clinical breast cancer. 
2004; 5:371–376. [PubMed: 15585076] 
41. Hurley J, Reis I, Silva O, Gomez C, DeZarraga F, Velez P, et al. Weekly docetaxel/carboplatin as 
primary systemic therapy for HER2-negative locally advanced breast cancer. Clinical breast 
cancer. 2005; 5:447–454. [PubMed: 15748465] 
42. Martin M, Romero A, Cheang MC, Lopez Garcia-Asenjo JA, Garcia-Saenz JA, Oliva B, et al. 
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast 
Cancer Res Treat. 2011; 128:127–136. [PubMed: 21465170] 
43. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to 
neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a 
single-institution experience. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2011; 29:3739–3746. [PubMed: 21900106] 
44. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete 
response predicts recurrence-free survival more effectively by cancer subset: results from the I-
SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2012; 30:3242–3249. [PubMed: 22649152] 
45. Cortazar P, Geyer CE Jr. Pathological complete response in neoadjuvant treatment of breast cancer. 
Annals of surgical Oncology. 2015; 22:1441–1446. [PubMed: 25727556] 
46. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Event-free and 
overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/− carboplatin 
Sharma et al. Page 12
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). 38 
Annual SABCS. 2015
47. Von Minckwitz, GLS., Schneeweiss, A., et al. Early survival analysis of the randomized phase II 
trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-
positive early breast cancer (GeparSixto). San Antonio, Texas: San Antonio Breast Cancer 
Symposium; 2015. 
48. Andres R, Pajares I, Balmana J, Llort G, Ramon YCT, Chirivella I, et al. Association of BRCA1 
germline mutations in young onset triple-negative breast cancer (TNBC). Clinical & translational 
oncology : official publication of the Federation of Spanish Oncology Societies and of the 
National Cancer Institute of Mexico. 2014; 16:280–284.
49. Zugazagoitia J, Perez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, et al. Limited family 
structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a 
genetic counseling cohort of early-onset sporadic breast cancers. Breast cancer research and 
treatment. 2014; 148:415–421. [PubMed: 25342642] 
50. Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al. Pathologic complete 
response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast cancer research 
and treatment. 2014; 147:401–405. [PubMed: 25129345] 
Sharma et al. Page 13
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Translational Relevance
Pathological and molecular similarities between sporadic and germline BRCA mutation 
breast cancers associated and Triple negative breast cancer (TNBC) have led to the 
exploration of DNA damaging agents like platinum compounds in TNBC. In this 
manuscript we report robust pathological complete response rates in 190 patients treated 
with anthracycline-free chemotherapy regimen of carboplatin plus docetaxel. Germline 
BRCA1/2 mutations may be an important biomarker of response to platinum agents in 
TNBC. It has been speculated that improvement in pCR noted with addition of 
carboplatin to traditional chemotherapy in TNBC may be driven primarily by high 
responses in germline BRCA mutation carriers. However, this platinum-taxane 
chemotherapy regimen rendered equally high pathological complete response rates in 
BRCA-associated (pCR of 59%) and BRCA-wildtype (pCR of 56%) TNBC. The results 
of our study support further evaluation of platinum-chemotherapy in both BRCA-
associated and wildtype TNBC.
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Figure 1. 
CONSORT diagram
*In addition to the various centers in Spain, the Spanish cohort includes a center from Lima, 
Peru
Sharma et al. Page 15
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Carboplatin plus Docetaxel pathological response by gBRCA status
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Table 1
Patient Demographics
All Patients KU Spanish
P*(N=190) (N=69) (N=121)
Age at Diagnosis (years)
(Median , Range)
51
(29–81)
52
(30–80)
50
(29–81) 0.86
Race
    Caucasian 174 (92%) 57 (83%) 117 (96%)
<0.001    Black 14 (7%) 12 (17%) 2 (2%)
    Asian 2 (1%) 0 (0%) 2 (2%)
Ethnicity
    Hispanic 26 (14%) 2 (3%) 24 (20%) 0.001
    Non-Hispanic 163 (86%) 67 (97%) 97 (80%)
Menopausal status
    Pre/Peri 86 (45%) 30 (44%) 56 (46%) 0.59
    Post 98 (52%) 38 (55%) 60 (50%)
    Unknown 6 (3%) 1 (1%) 5 (4%)
T Stage Number
    1 23 (12%) 19 (27%) 4 (3%)
<0.001
    2 104 (55%) 37 (54%) 67 (55%)
    3 34 (18%) 11 (16%) 23 (19%)
    4 29 (15%) 2 (3%) 27 (23%)
Median Tumor Size (mm)
(range)
35 (9–180) 30.5 (10–111) 41(9–180) <0.001
Lymph Node Status
    Negative 90 (47%) 47 (68%) 43 (35%) <0.001
    Positive 98 (52%) 22 (32%) 76 (63%)
    Unknown 2 (1%) 0 (0%) 2 (2%)
TNM Stage
    I 20 (11%) 18 (26%) 2 (2%) <0.001
    II 107 (56%) 41 (59%) 66 (54%)
    III 63 (33%) 10 (15%) 53 (44%)
ER/PR
    0% 184 (97%) 63 (91%) 121(100%) 0.001
    1–10% 6 (3%) 6 (9%) 0 (0%)
Germline BRCA Mutation
    Absent 136 (71%) 49 (71%) 87 (72%)
0.084    Present 30 (16%) 15 (22%) 15 (12%)
    Unknown 24 (13%) 5 (7%) 19 (16%)
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All Patients KU Spanish
P*(N=190) (N=69) (N=121)
Surgery type#
    Lumpectomy 84 (45%) 23 (33%) 61 (53%) 0.045
    Mastectomy 101 (55%) 46 (67%) 55 (47%)
Axillary surgery
  Pre NAC SLNB 24 (13%) 0 (0%) 24 (20%) <0.001 
  Post NAC
    SLNB without ALND 50 (27%) 46 (66%) 4 (3%) <0.001
    SLNB plus ALND 15 (8%) 6 (9%) 9 (8%)
    ALND 94 (50%) 15 (22%) 79 (66%)
    No axillary procedure 5 (2%) 2 (3%) 3 (3%)
Positive family History⍰
    Yes 52 (28%) 27 (39%) 25 (21%) 0.11
    No 136 (72%) 42 (61%) 94 (79%)
*
Mann-Whitney non-parametric test for continuous data; Pearson Chi-Square/Fisher Exact test for categorical data.
#Surgical information was not available for 5 patients in the IIT population.
⍰
Family history information was not available for 2 patients from Spanish-cohort. Family history is reported utilizing cohort specific definitions of 
positive family history as outlined in patient characteristics section. Upon application of Spanish family history definition to the entire study 
population, 24% of patients had positive family history
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Table 2
Pathological response by germline BRCA mutation status and Stage
All Patients KU Spanish P*
All patients N=183 N=68 N=115
pCR N (%) (95% CI) N (%) (95% CI) N (%) (95% CI)
    Yes 100 (55%) (48%, 62%) 44 (65%) (54%, 76%) 56 (49%) (40%, 58%) 0.046
    No 83 (45%) (38%, 52%) 24 (35%) (24%, 46%) 59 (51%) (42%, 60%)
RCB 0 +1
    Yes 125 (68%) (61%, 75%) 55 (81%) (72%, 90%) 70 (61%) (52%, 70%) 0.005
    No 58 (32%) (25%, 39%) 13 (19%) (10%, 28%) 45 (39%) (30%, 48%)
BRCA wild type N=133 N=48 N=85
pCR N (%) (95% CI) N (%) (95% CI) N (%) (95% CI)
    Yes 75 (56%) (48%, 64%) 31 (65%) (52%, 78%) 44 (52%) (41%, 63%) 0.20
    No 58 (44%) (36%, 52%) 17 (35%) (22%, 48%) 41 (48%) (37%, 59%)
RCB 0 +1
    Yes 92 (69%) (61%, 77%) 39 (81%) (70%, 92%) 53 (62%) (52%, 72%) 0.031
    No 41 (31%) (23%, 39%) 9 (19%) (8%, 30%) 32 (38%) (28%, 48%)
BRCA mutation positive N=27 N=15 N=12
pCR N (%) (95% CI) N (%) (95% CI) N (%) (95% CI)
    Yes 16 (59%) (40%, 78%) 11 (73%) (51%, 95%) 5 (42%) (14%, 70%) 0.13
    No 11 (41%) (22%, 60%) 4 (27%) (5%, 49%) 7 (58%) (30%, 86%)
RCB 0+1
    Yes 19 (70%) (53%, 87%) 12 (80%) (60%, 100%) 7 (58%) (30%, 86%) 0.40
    No 8 (30%) (13%, 47%) 3 (20%) (0%, 40%) 5 (42%) (14%, 70%)
BRCA status unknown N=23 N=5 N=18
pCR N (%) (95% CI) N (%) (95% CI) N (%) ( 95% CI) 1
    Yes 9 (39%) (19%, 59%) 2 (40%) (3%, 83%) 7 (39%) (16%, 62%)
    No 14 (61%) (41%, 81%) 3 (60%) (17%, 103%) 11 (61%) (38%, 84%)
RCB 0 +1
    Yes 14 (61%) (41%, 81%) 4 (80%) (45%, 115%) 10 (56%) (33%, 79%) 0.61
    No 9 (39%) (19%, 56%) 1 (20%) (15%, 55%) 8 (44%) (21%, 67%)
TNM stage I and II N=124 N=58 N=66
pCR N (%) (95% CI) N (%) (95% CI) N (%) ( 95% CI)
    Yes 78 (63%) (54%, 71%) 40 (69%) (57%, 81%) 38 (58%) (46, 70%) 0.20
    No 48 (37%) (29%, 46%) 18 (31%) (19%, 43%) 28(42%) (30%, 54%)
RCB 0 +1
    Yes 95 (77%) (70%, 84%) 50 (86%) (77%, 95%) 45 (68%) (57%, 79%) 0.02
    No 29 (23%) (16%, 30%) 8 (14%) (5%, 23%) 21 (32%) (21%, 43%)
TNM stage III N=59 N=10 N=49
pCR N (%) (95% CI) N (%) (95% CI) N (%) (95% CI)
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All Patients KU Spanish P*
    Yes 22 (37%) (25%, 49%) 4 (40%) (10%, 70%) 18 (37%) (23%, 51%) 1.0
    No 37 (63%) (51%, 75%) 6 (60%) (30%, 90%) 31(63%) (49%, 77%)
RCB 0 + 1
    Yes 29 (49%) (36%, 62%) 5 (50%) (19%, 81%) 24 (49%) (35%, 63%) 1.0
    No 30 (51% (38%, 64%) 5 (50%) (19%, 81%) 25 (51%) (37%, 65%)
*
Fisher Exact test.
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Table 3
Predictors of pathological complete response on univariate analysis#
OR 95% CI P*
Age
≤50 1
>50 0.74 0.4, 1.33 0.37
LN status
    Negative 1
    Positive 0.71 0.39, 1.27 0.30
T stage
    T1/2 1
    T3/4 0.39 0.21,0.73 0.003
TNM stage
    I/ II 1
    III 0.35 0.19, 0.67 0.001
gBRCA mutation
    Negative/unknown 1
    Positive 1.25 0.54, 2.86 0.68
Family History
No 1
Yes 0.96 0.5, 1.85 1.0
Cohort
    Spanish 1
    KU 1.93 1.04, 3.50 0.046
*Odds ratios (ORs) and 2-sided P values from Fisher’s exact test.
#On multivariable logistic regression analysis (factors included: age, lymph node status, T stage, TNM stage, germline BRCA mutation status, 
family history and cohort type) presence of TNM stage III disease was the only factor associated with a lower likelihood of achieving a pCR (HR 
0.35, 95% CI: 0.19, 0.67)
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Table 4
Grade 3 or 4 Treatment-Related Toxicities 
N = 190 G 3/4 n (%) G3 n (%) G4 n (%)
Leukopenia 2 (1%) 2 (1%) 0 (0%)
Neutropenia 22 (12%) 13 (7%) 9 (5%)
Thrombocytopenia 11 (6%) 9 (5%) 2 (1%)
Anemia 7 (4%) 6 (3%) 1 (1%)
Febrile Neutropenia 8 (4%) 6 (3%) 2 (1%)
Nausea 5 (3%) 5 (3%) 0 (0%)
Vomiting 5 (3%) 4 (2%) 1 (1%)
Mucositis 2 (1%) 2 (1%) 0 (0%)
Diarrhea 5 (3%) 5 (3%) 0 (0%)
Peripheral Neuropathy 3 (2%) 3 (2%) 0 (0%)
Fatigue 2 (1%) 2 (1%) 0 (0%)
Other* 9 (5%) 9 (5%) 0 (0%)
*Other: Hepatic/transaminase elevation (n=3), rash (n=2), hyponatremia (n=1), thrombosis (n=1), allergic reaction (n=1), dehydration (n=1)
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